PLAINSBORO, N.J., Jan. 26, 2016 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, today announced the availability of its newest insulin, Tresiba® (insulin degludec injection), a ...
If you have diabetes, your doctor might suggest Tresiba (insulin degludec) as a treatment option for you. Tresiba is a prescription medication. It’s used long term to manage blood sugar levels in ...
Novo Nordisk announced the launch of Tresiba (insulin degludec) injection indicated to improve glycemic control in adults with diabetes. Novo Nordisk announced the launch of Tresiba (insulin degludec) ...
Tresiba (insulin degludec) is a brand-name drug that’s prescribed for diabetes. The medication is available as a liquid vial and a prefilled injection pen. The cost of Tresiba with and without ...
Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted positive opinions, recommending marketing authorisations, ...
Bagsværd, Denmark, 29 January 2016 - Novo Nordisk today announced the headline results from SWITCH 2, the first of two 2x32-weeks randomised, double-blind, cross-over, treat-to-target trials, ...
Novo Nordisk announced the submission of a supplemental application to the Food and Drug Administration (FDA) which includes data from the DEVOTE study, a trial that assessed the cardiovascular safety ...
Concern about overnight hypoglycemic events drives decision-making for patients with type 1 diabetes. For persons with type 1 diabetes (T1D) fear of the overnight hypoglycemic event drives care ...
As with other drugs, Tresiba (insulin degludec) can cause side effects, such as headache, upper respiratory infection, and injection site reaction. If side effects of Tresiba become difficult to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback